Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GRI Bio, Inc. (GRI)

GRI Bio receives FDA Orphan Drug Designation for GRI-0621 in IPF

Neutral Impact 3 of 5 legal/regulatory Written later

GRI Bio said on June 18, 2026 that the U.S. Food and Drug Administration granted Orphan Drug Designation to GRI-0621, its oral investigational therapy for idiopathic pulmonary fibrosis (IPF). The designation provides potential benefits such as seven years of U.S. market exclusivity upon approval, but the filing does not report revenue, earnings, or changes to guidance.

Key points

  • FDA granted Orphan Drug Designation to GRI-0621 for IPF, announced June 18, 2026
  • Orphan designation applies to diseases affecting fewer than 200,000 people in the U.S.; benefits include potential seven years of U.S. market exclusivity upon approval
  • GRI-0621 was evaluated in a 35-patient Phase 2a trial (GRI-0621-IPF-02), which the company says met its primary, secondary and exploratory endpoints

The filing

CompanyGRI Bio, Inc. (GRI)
Form8-K, current report
Filed with the SECJun 18, 2026, 4:50 PM ET
Accession number0001824293-26-000050

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.